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of biological sample exploitation. During PK calculations, many 
researchers merely use for dose the nominal amount declared, over-
looking the noticeable biases that may result in the assessment of PK 
parameters. The aim of this work was to evaluate the biases related 
to doses injected of a biosimilar drug in 2 Phase I clinical trials.
Patients (or Materials) and Methods: In trial A, 12 healthy volun-
teers received different doses of a biosimilar of interferon beta-1a by 
either subcutaneous (SC) or intravenous (IV) injection. The doses 
were prepared by partially emptying 0.5-mL syringes supplied by 
the manufacturer (drop count procedure). In trial B, 12 healthy vol-
unteers received 3 different formulations of the drug by IV injection 
(biosimilar without albumin [HSA], biosimilar with HSA and original 
brand [Rebif®]) and 2 different formulations as multiple SC injec-
tions (biosimilar HSA-free and original brand). In both trials, the 
actual dose administered was calculated as: D = C·V – losses. The 
product titer C was assessed by ELISA. The volume administered IV 
was assessed by weighting. Losses were evaluated by in vitro experi-
ments. Finally, the binding of 125I-interferon to HSA was evaluated 
by counting the free and HSA complexed molecule fractions sepa-
rated by gel filtration.
Results: Interferon was not significantly adsorbed onto the lines used 
for its IV administration. In trial A, the titer was very close to the one 
declared (96 ± 7%). In trial B, it differed significantly (156 ± 10% 
for biosimilar with/without HSA and 123 ± 5% for original for-
mulation). In trial A, the dose actually administered showed a large 
variability. The real injected volume could be biased up to 75% com-
pared with the theoretical volume (for the lower dose administered 
[ie, 0.03 mL]). This was mainly attributed to a partial re-aspiration 
of the drug solution before withdrawing the syringe needle. A strict 
procedure was therefore applied in trial B to avoid these inaccuracies. 
Finally, in trial B, 125I-Interferon beta-1a binding to HSA appeared 
time dependent and slow, reaching 50% after 16-hour incubation, 
which is close to steady state reported for the comparator Rebif®.
Conclusion: These practical examples (especially biases on actual 
titer and volume injected) illustrate that actual dose assessment 
deserves attention to ensure accuracy for estimates of clearance and 
distribution volume in the scientific literature and for registration 
purposes, especially for bioequivalence studies.
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Introduction: Increasing efforts have been made on the research 
of new predictive biomarkers in drug development, particularly in 
oncology. In this context, the validation process represents a difficult 
task with some potential methodologic limitations. In the present 
study, we will perform a critical review of the validation process of 
6 key biomarkers in oncology.
Patients (or Materials) and Methods: Six biomarkers were selected 
considering their relevance in drug development over the last dec-
ade in oncology: HER-2, EGFR, KRAS, C-KIT ALK, and C-Met. 
A review of literature was performed in PubMed, Cochrane, and 
EMBASE, and in regulatory agencies public websites. A critical 
review of available data in relation to regulatory requirements (EMA 
and FDA) has been conducted considering the following elements: 
at which stage of drug development the biomarker was considered 
in defining the target population; type of clinical data used for the 
biomarker validation process; impact of the biomarker in the final 
labeling; and availability of a standardized test applicable in clinical 
practice.
Results: Results are displayed according to recommendations of 
regulatory agencies on the necessary procedural steps for the valida-
tion process preapproval.
Conclusion: Data analyzed allow to distinguish 2 different scenarios. 
Those situations in which the biomarker development was the con-
sequence of a primarily failing drug development strategy (EGFR 
and KRAS) and those in which the biomarker was a key element 
prospectively considered in drug development (ALK, HER2, C-KIT 
and C-met). Regulatory decisions were adopted sometimes based on 
purely retrospective strategies. The authors will critically describe 
such circumstances and the potential clinical implications of such 
decisions.
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Introduction: An integrated final exam for medical students was 
introduced at Karolinska Institutet, Stockholm, Sweden, in 2012. 
The exam is scenario based and consists of six 20-minute stations, 
1 of which has been designed to assess clinical pharmacology (CP) 
skills. The overall aim of the exam is to assess the knowledge (both 
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clinical and preclinical) and skills needed to perform adequately dur-
ing the following 18 month internship that is required to obtain the 
medical license. CP contents, results, and student perceptions from 
the first 3 occasions are presented.
Patients (or Materials) and Methods: The examination takes place in 
the last semester of the 5.5-year training program. The 6 stations are 
equally weighted in the total result. The students can pass the exam if 
they fail at 1 station, as long as their average score is sufficient. The 
CP station has consisted of a computer-presented patient case with 
questions, aimed at assessing prescribing skills and has also included 
preclinical aspects. Students have been allowed to use the Internet to 
search for information but not to interact with other persons. The 
cases so far have included the evaluation of possible side effects in 
an elderly patient with polypharmacy admitted after falling, drug 
prescribing to a pregnant woman with a urinary tract infection and 
migraine, and the reasoning about terminating or continuing treat-
ment with several medicines initiated by another prescriber. Students’ 
perceptions of the exam were collected through group interviews or 
questionnaires in direct connection to examination.
Results: Five percent of students failed the exam as a whole, whereas 
the failure rate at the CP station was somewhat higher; 7% to 14%. 
The failure rate was higher at the stations with more theoretical 
content such as CP, compared with stations assessing skills in com-
munication and physical examination or procedures. Within the CP 
station, preclinical questions had a higher failure rate than the more 
clinically oriented. Also, only 16% of prescription forms were filled 
out correctly. Students’ comments have included that it is essential 
that the scenarios are perceived as authentic and that it is difficult to 
go from practical stations, like a cardiac resuscitation scenario, to 
“computer patients.” A few technical problems with the computers 
were perceived as very disturbing.
Conclusion: A clinical pharmacology station can be a valuable part 
of an integrated final exam and is well suited for the assessment 
of practical prescribing performances, as well as students' abilities 
to integrate preclinical knowledge and clinical reasoning. Scenarios 
must be perceived as authentic, and access to the Internet can thus 
be a natural part of the setting.
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Introduction: In contrast to the diagnostic part of the medical record 
(MR), the therapeutic section of the MR is currently unstructured 
and does not provide guidelines on which items of the (pharmaco)
therapy are essential to note in the MR. The omission of this infor-
mation could result in prescribing errors and miscommunication 
between doctors. A previous study showed that both junior doc-
tors and clinical consultants believe it is important to note extensive 
information in the MR about the selected (pharmaco) therapy. This 
study investigated the effect of a structured MR on the completeness 
of therapeutic information in the MR and the extent to which doctors 
felt informed about the treatment (as an indicator of communication 
between doctors).
Patients (or Materials) and Methods: Fifteen junior doctors work-
ing in the outpatient department of internal medicine in 7 Dutch 
teaching hospitals recorded therapeutic information for 2 weeks in 
regular, unstructured MRs. Subsequently after receiving a short train-
ing, they had to record their therapeutic information for 4 weeks in 
a structured MR. The structure contained 21 therapeutic items that 
should be recorded. The recording of these therapeutic items was then 
evaluated in 223 unstructured MRs and 197 structured MRs. After 
this evaluation, independent clinical consultants in internal medicine 
were asked to score, on a 5-point scale, the extent to which they felt 
informed about the treatment.
Results: Seven of the 21 (33%) therapeutic items were recorded in sig-
nificantly (P < 0.05) greater detail in the structured MRs. Clinical con-
sultants did not feel significantly more informed about treatment (score 
3.9 with unstructured MRs and 4.0 with structured MRs; P = 0.25).
Conclusion: Structuring the therapeutic part of the MR improves 
the documentation of therapeutic information, but doctors did not 
feel more informed about the treatment.
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Introduction: The Scottish Medicines Consortium (SMC) provides 
advice about the clinical and cost-effectiveness of newly licensed 
medicines to the National Health Service (NHS) in Scotland, and 
since 2005, SMC has also provided early intelligence on medicines 
still in development through publication of “Forward Look” reports. 
Forward Look predictions are helpful in supporting resource plan-
ning by NHS Boards, but there are challenges in accurately estimating 
the uptake of a medicine that is still in development. This study exam-
ined how actual medicine use compared with predictions provided 
in Forward Look Reports and SMC advice.
Patients (or Materials) and Methods: Twenty-eight medicines were 
selected in line with specified criteria. Data on the predicted uptake 
of these medicines at year 1 were extracted from Forward Look 
reports and SMC advice and compared with actual medicine use 
data from national primary and secondary care datasets. The data 
were summarized in medicine profiles and reviewed by clinicians to 
identify factors that may have impacted on the accuracy of predic-
tions provided in Forward Look reports and SMC advice.
Results: Of 28 medicines selected for evaluation, the actual acquisi-
tion cost per patient per annum was consistent with Forward Look 
predictions for 11 medicines, higher for 14 medicines, and lower for 
3 medicines. Of 22 medicines in the sample that were accepted for use 
or restricted use by SMC, the actual uptake at year 1 was consistent 
with Forward Look predictions for 4 medicines and with predictions 
in SMC advice for 3 medicines. Forward Look was more likely to 
overestimate the uptake than the SMC advice. Review of the medicine 
profiles identified 7 factors that may explain the variation between 
predicted and actual medicines uptake
- SMC “not recommended” advice
-  Accuracy of the predicted acquisition cost and number of patients 
(uptake being the product of these)
- Availability of alternative treatment
- Comparative costs and service implications
